Parra S, Pinochet R, Vargas R, Sepúlveda C, Miranda D, Puente J
Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago de Chile.
Rev Med Chil. 1994 Jun;122(6):630-7.
Natural killer cytolytic activity, the basis of cancer immunotherapy that uses cytolytic cells, may be impaired in cancer. The aim of this work was to study in vitro the natural killer cytolytic activity and its response to the immunomodulators interleukin-2, interferon and phytohemagglutinin stimulated lymphocyte proliferation in a group of 9 patients with renal cell cancer and 6 with prostatic cancer. The results were compared with those of 20 normal volunteers. Twelve patients were operated and were studied twice 48 h and 14 days after surgery. Natural killer cytolytic activity was significantly lower in renal cell and prostatic cancer patients than controls (3.3 +/- 1.6, 4.9 +/- 2.2 and 20.6 +/- 3.7% of specific lysis respectively). This activity was not modified in cancer patients by interleukin-2 50 UI/ml or interferon 3000 UI/ml and did not differ in the two postoperative periods. Phytohemagglutinin stimulated lymphocyte proliferation was also lower in cancer patients, compared to controls (stimulation index of 18 +/- 3 and 26.5 +/- 5 respectively). It is concluded that these patients have a low immunological level and that this study is the first step towards an immunological characterization of cancer patients that are candidate to adoptive immunotherapy.
自然杀伤细胞的细胞溶解活性是使用细胞溶解细胞进行癌症免疫治疗的基础，但在癌症患者中可能会受到损害。本研究的目的是在体外研究9例肾细胞癌患者和6例前列腺癌患者的自然杀伤细胞溶解活性及其对免疫调节剂白细胞介素-2、干扰素和植物血凝素刺激的淋巴细胞增殖的反应。将结果与20名正常志愿者的结果进行比较。12例患者接受了手术，并在术后48小时和14天进行了两次研究。肾细胞癌和前列腺癌患者的自然杀伤细胞溶解活性明显低于对照组（特异性溶解分别为3.3±1.6%、4.9±2.2%和20.6±3.7%）。50 UI/ml的白细胞介素-2或3000 UI/ml的干扰素对癌症患者的这种活性没有影响，且两个术后时期的活性没有差异。与对照组相比，癌症患者中植物血凝素刺激的淋巴细胞增殖也较低（刺激指数分别为18±3和26.5±5）。结论是这些患者的免疫水平较低，并且这项研究是对作为过继性免疫治疗候选者的癌症患者进行免疫特征分析的第一步。
